Last updated: July 11, 2026
Forest Laboratories, LLC v. Amerigen Pharmaceuticals, Inc. (1:16-cv-00917): Litigation Summary, Patent Issues, and Commercial Impact
Executive summary
Forest Laboratories, LLC sued Amerigen Pharmaceuticals, Inc. in the U.S. District Court for the District of Delaware (case No. 1:16-cv-00917) in 2016. The docket indicates a patent infringement dispute tied to an FDA regulatory filing by Amerigen, framed through the Hatch-Waxman framework (Orange Book patents and 35 U.S.C. § 271(e)(2)). The litigation posture is consistent with a Paragraph IV type challenge and an attempt by Forest to block or delay generic launch pending resolution of patent validity and infringement. The case also functions as a benchmark for Forest’s broader strategy to preserve exclusivity around its portfolio through active enforcement against ANDA filers.
What patents were at issue in Forest v. Amerigen (1:16-cv-00917)?
Answer: The specific asserted patents are not identifiable from the information provided in the prompt.
Because the request is limited to a docket-style identifier and no complaint, patent list, or Orange Book mapping details are included, a complete and accurate patent-by-patent summary cannot be produced.
Which brands or active ingredients were implicated?
Answer: Not identifiable from the information provided.
Were method-of-use, formulation, or manufacturing patents asserted?
Answer: Not identifiable from the information provided.
What claims were alleged under 35 U.S.C. § 271(e)(2)?
Answer: The case structure implies an ANDA/Orange Book dispute under § 271(e)(2), but the actual claim set and the specific “infringes” theory (ANDA process, proposed labeling, proposed formulation, or use instructions) are not identifiable from the information provided.
When did the parties file key litigation steps in 1:16-cv-00917?
Answer: Not identifiable from the information provided.
Complaint and service timeline
Answer: Not identifiable from the information provided.
Claim construction or dispositive motion milestones
Answer: Not identifiable from the information provided.
Trial, settlement, or dismissal events
Answer: Not identifiable from the information provided.
What was the procedural posture (motions, Markman, or consolidation) in Forest v. Amerigen?
Answer: Not identifiable from the information provided.
Were there motions to dismiss for pleading sufficiency or improper venue?
Answer: Not identifiable from the information provided.
Did the court address venue transfer or jurisdiction challenges?
Answer: Not identifiable from the information provided.
What did Forest seek to obtain and what remedies were requested?
Answer: Not identifiable from the information provided.
Injunction scope
Answer: Not identifiable from the information provided.
Damages
Answer: Not identifiable from the information provided.
Enhanced remedies
Answer: Not identifiable from the information provided.
How did the case fit into FDA ANDA exclusivity and Paragraph IV risk?
Answer: The litigation is consistent with Hatch-Waxman patent enforcement in response to an ANDA.
What Orange Book status typically drives cases like this?
Answer: Such cases commonly center on one or more Orange Book-listed patents, with disputes over whether the generic’s proposed product infringes and whether the patents are invalid and/or unenforceable.
How does § 271(e)(2) framing affect outcomes?
Answer: It usually turns the case into a validity and infringement contest without requiring proof of commercial sale before approval.
What is the strength of the Forest patent estate implicated by 1:16-cv-00917?
Answer: Not measurable from the information provided.
Patent term remaining at filing (expiration and enforceability)
Answer: Not identifiable from the information provided.
Known enforceability risks (obviousness-type double patenting, written description, enablement)
Answer: Not identifiable from the information provided.
Which companies typically litigate alongside Forest in similar Delaware Hatch-Waxman matters?
Answer: Not identifiable from the information provided.
Were other defendants or related cases consolidated?
Answer: Not identifiable from the information provided.
What was Amerigen’s litigation posture (non-infringement and validity defenses)?
Answer: Not identifiable from the information provided.
Common defenses in this posture
Answer: Not identifiable from the information provided, but cases in this category usually include non-infringement and invalidity arguments under §§ 102, 103, 112, and inequitable conduct theories.
Did the parties reach a settlement, and if so, what were the deal terms and triggers?
Answer: Not identifiable from the information provided.
Typical settlement components (not confirmed for this docket)
Answer: Not confirmed for this docket, but settlements often include authorized launch dates, carve-outs around additional patents, and covenants not to sue.
What was the outcome: did Amerigen launch, and when did generics enter?
Answer: Not identifiable from the information provided.
Generic launch risk vs. brand exclusivity
Answer: Not identifiable from the information provided.
Commercial impact: How much revenue was at stake and what did the litigation change?
Answer: Not identifiable from the information provided.
Revenue exposure linked to exclusivity
Answer: Not identifiable from the information provided.
Market share or pricing impact
Answer: Not identifiable from the information provided.
How does this case compare with other Forest Laboratories generic-enforcement actions?
Answer: Not identifiable from the information provided.
Comparative metrics that require docket and patent detail
Answer: Not identifiable from the information provided.
Key Takeaways
- Forest Laboratories, LLC sued Amerigen Pharmaceuticals, Inc. in District of Delaware case No. 1:16-cv-00917 in 2016 in a Hatch-Waxman style patent enforcement posture.
- The docket number alone is insufficient to identify asserted patents, claim theories, litigation dates, rulings, settlement terms, or launch outcomes.
- For business decisions tied to licensing, freedom-to-operate, or competitor entry risk, the absence of patent-specific and outcome-specific facts prevents a complete, accurate infringement and exclusivity analysis.
FAQs
- What court and jurisdiction handled Forest Laboratories v. Amerigen (1:16-cv-00917)?
- Does a Hatch-Waxman case like this always involve Paragraph IV certifications?
- How do Orange Book patent listings typically map to asserted claims in ANDA litigation?
- What settlement terms most commonly delay generic launch in Delaware Hatch-Waxman cases?
- How should a pharma team use docket data to build an exclusivity and generic-entry timeline?
References (APA)
- U.S. District Court for the District of Delaware. (2016). Forest Laboratories, LLC v. Amerigen Pharmaceuticals, Inc., No. 1:16-cv-00917.
